Metastatic Castration-resistant Prostate Cancer Clinical Trials in Palo Alto, California

5 studies are recruiting for metastatic castration-resistant prostate cancer in Palo Alto, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford Cancer Institute, Stanford University, Palo Alto, California

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

2. A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

   The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford Cancer Center, Palo Alto, California

   Locations

   15 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06067841 on ClinicalTrials.gov

3. A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

   The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Palo Alto, California

   Locations

   16 in total

   Run by

   AstraZeneca

   See if you can join NCT06879041 on ClinicalTrials.gov

4. A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

   This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main purpose of the study is to look at the safety, tolerability (…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University Medical Center - Blake Wilbur Drive, Palo Alto, California

   Locations

   14 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT05125016 on ClinicalTrials.gov

5. A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

   The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with P…

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Stanford University, Palo Alto, California

   Locations

   21 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06531499 on ClinicalTrials.gov